In Silico ADME Tools

  • Siamak Cyrus KhojastehEmail author
  • Harvey Wong
  • Cornelis E. C. A. Hop


The breath and predictive power of in silico ADME tools has increased rapidly during the last 10 years. The quality of many models is such that they can successfully influence decision making in drug discovery and development. In drug discovery they can influence decision related to synthesis of compounds and in development they can influence decisions to perform certain clinical trials or the design of the trial.


Partial Little Square Plasma Protein Binding PBPK Model Metabolic Stability Compartmental Transit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Compartmental absorption and transit model


Physiologically based pharmacokinetic model


Cytochrome P450


Partial least squares


Structure–activity relationship


Support vector machine


  1. Cruciani G, Carosati E, De Boeck B et al (2005) MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970–6979PubMedCrossRefGoogle Scholar
  2. Gao H, Yao L, Mathieu HW et al (2008) In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos 36:2130–2135PubMedCrossRefGoogle Scholar
  3. Gleeson MP, Davis AM, Chohan KK (2007) Generation of in–silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J Comput Aided Mol Des 21:559–573PubMedCrossRefGoogle Scholar
  4. Lavé T, Parrott N, Grimm HP et al (2007) Challenges and opportunities with modeling and simulation in drug discovery and drug development. Xenobiotica 37:1295–1310PubMedCrossRefGoogle Scholar
  5. Lee PH, Cucurull-Sanchez L, Lu J et al (2007) Development of in silico models for human liver microsomal stability. J Comput Aided Mol Des 21:665–673PubMedCrossRefGoogle Scholar
  6. Stoner CL, Troutman M, Gao H et al (2006) Moving in silico screening into practice: A minimalist approach to guide permeability screening. Lett Drug Des Discov 3:575–581CrossRefGoogle Scholar

Additional Reading

  1. Espié P, Tytgat D, Sargentini–Maier M-L et al (2009) Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391–407Google Scholar
  2. Hou T, Wang J (2008) Structure–ADME relationship: still a long way to go. Expert Opin Drug Metab Toxicol 4:759–770PubMedCrossRefGoogle Scholar
  3. Kharkar PS (2010) Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. Curr Top Med Chem 10:116–126CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Siamak Cyrus Khojasteh
    • 1
    Email author
  • Harvey Wong
    • 1
  • Cornelis E. C. A. Hop
    • 1
  1. 1.Genentech, Inc.San FranciscoUSA

Personalised recommendations